$12.62
arrow_drop_down2.84%Viatris Inc has a market capitalization of $14.83 billion and an enterprise value of $32.29 billion, indicating the company's value in the market. The price to sales ratio of 0.95 suggests that the stock is relatively undervalued compared to its revenue generation. The company's dividend yield of 3.81% is attractive for income investors, providing a steady income stream. Additionally, Viatris Inc has a strong free cash flow margin of 20.59%, indicating its ability to generate cash for growth and dividends. The company's return on assets of 2.79% and return on equity of 0.26% reflect its efficiency in utilizing assets and generating profits for shareholders. On the other hand, Viatris Inc's high price-to-earnings ratio of 247.2 may indicate that the stock is overvalued in the market. The company's net margin of only 0.35% reflects its low profitability and potential challenges in maintaining sustainable earnings growth. The debt-to-equity ratio of 0.9 suggests a balanced mix of debt and equity financing, providing stability for the company's operations. The operating margin of 13.68% indicates the company's ability to generate profits from its core business activities. Lastly, the historical dividend yield average of 3.85% suggests a consistent track record of dividend payments, making Viatris Inc an appealing investment option for income-oriented investors.
Viatris Inc has reported a strong Q4 earnings with a focus on growing its base business, which includes both generic and branded drugs. The company has announced a research partnership with Switzerland-based biotech Idorsia, which could lead to future growth opportunities. Viatris has been forecasting strong sales for 2024, indicating a potential increase in revenue.
The company has reported a loss of $765.6 million in its fourth quarter, indicating a significant decrease in profitability. The company's Q4 earnings and revenues missed estimates, which could impact its stock price negatively. The company has a high debt-to-equity ratio of 0.837, which could pose a risk to its financial health.
Viatris Inc (VTRS) has a mixed technical analysis outlook with one buy indicator, six hold indicators, and one sell indicator for the month. The stock currently has a neutral technical rating, suggesting that investors may want to exercise caution when considering trading opportunities. The stock's price performance over the past seven days showed a significant decline of 7.98%, indicating a short-term bearish trend. Additionally, the stock's price has experienced a decline of 1.83% compared to the previous close, suggesting potential downside pressure. On the positive side, the stock's technical indicators also show some potential for a rebound, with a current price discount of 83.45% compared to its all-time high and a low debt-to-equity ratio of 0.9. The stock's quick ratio of 4.89 suggests that the company has an adequate level of liquidity to meet its short-term obligations. However, investors should also consider the stock's high trailing PE ratio of 251.8 and negative return on assets of -0.26%, indicating potential challenges in profitability and efficiency. Overall, investors may want to closely monitor Viatris Inc's technical indicators and market performance before making any trading decisions.
Based on the data provided, Viatris Inc (VTRS) is a stock in the healthcare sector with a current price of $12.36. The company has a market capitalization of $14.83 billion and a dividend yield of 3.81%. Viatris has shown positive growth in its revenue over the past year, with a net income of $54.7 million. Despite a high PE ratio of 247.2, the company has a strong free cash flow margin of 20.59%. In conclusion, Viatris Inc appears to be a stable investment option with consistent dividend payouts and a solid financial position. The company's forward annual dividend yield of 0.04% is lower compared to its historical dividend yield average of 3.85%. However, with a neutral analyst recommendation and a neutral technical rating, investors may want to monitor the stock closely for any potential changes in the market conditions or company performance. Overall, Viatris Inc shows promise for long-term growth potential but may require further analysis before making an investment decision.